Diranersen cut Alzheimer’s cognitive decline by 54% in a major trial
Health · Friday, November 20, 2026 · 3 sources

Diranersen cut Alzheimer’s cognitive decline by 54% in a major trial

Patients given low-dose diranersen injections had 54% less decline on a memory and thinking test over almost two years, according to The Telegraph. The drug uses gene-silencing technology to reduce production of tau, and is given by lumbar puncture; the result needs confirmation in a phase three trial.

Bottom line — UK recruitment for the next diranersen trial is expected to start in spring.

Go deeper 6

  1. Alzheimer’s Society research and innovation director Richard Oakley said the results were encouraging, but said the findings need confirmation in phase three.

  2. The CELIA trial results were announced at a clinical trials conference in Boston, according to The Independent.

  3. Diranersen targets tau by blocking RNA messages that tell brain cells to produce the protein, The Independent reported.

  4. The treatment is given by lumbar puncture into fluid around the spinal cord, The Independent reported.

  5. The Independent reported that the treatment is given twice a year.

  6. British patients are asking to join the next trial, with UK recruitment expected to begin in spring, The Telegraph reported.

Read the reporting 3

dstld. Your daily news summary designed to surface the news that matters from a European perspective. Curated by humans, summarized by AI - always with links back to the original reporting.

Links · Contact
Popular topics · WorldEuropeGamesAI
Last generated: Nov 20, 7:25 PM UTC by wreetco

dstld. Your daily news summary designed to surface the news that matters from a European perspective. Curated by humans, summarized by AI - always with links back to the original reporting.

Links · Contact
Popular topics · WorldEuropeGamesAI
Last generated: Nov 20, 7:25 PM UTC by wreetco